Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

Figure 5

Typical case of the Bahrain study. HbA1c in the patient under long-term therapy with high/maximum doses of oral hypoglycemic agents was dramatically improved by 5-ALA/SFC supplement (HbA1c decreased from 8.6 to 6.1 in 12 weeks) (unpublished data).